What's in Astellas Pharma Global Development, Inc.'s pipeline?

Astellas Pharma Global Development, Inc. has 45 drugs in our index: 1 marketed, 0 filed, 3 in Phase 3, 8 in Phase 2, 33 in Phase 1.

Which companies overlap with Astellas Pharma Global Development, Inc.'s portfolio?

Top competitors by shared drug class: GlaxoSmithKline, AstraZeneca, Pfizer, Merck Sharp & Dohme LLC, ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA).

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/astellas-pharma-global-development-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

Astellas Pharma Global Development, Inc. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Astellas Pharma Global Development, Inc. pipeline: 1 marketed, 0 filed, 3 Phase 3, 8 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 3 Phase 3 8 Phase 2 33 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Tacrolimus immediate release	Tacrolimus immediate release	marketed
ASP0113	ASP0113	phase 3	Therapeutic vaccine	CMV antigens (IE-1 and pp65)	Immunology / Infectious Disease
enfortumab vedotin (EV)	enfortumab vedotin (EV)	phase 3	Monoclonal antibody-drug conjugate	Nectin-4	Oncology
LoDAC (Low Dose Cytarabine)	LoDAC (Low Dose Cytarabine)	phase 3	Nucleoside analog; antimetabolite	DNA polymerase; thymidylate synthase	Oncology

Therapeutic area mix

Oncology · 5
Immunology · 4
Immunology / Infectious Disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

GlaxoSmithKline · 3 shared drug classes
AstraZeneca · 3 shared drug classes
Pfizer · 2 shared drug classes
Merck Sharp & Dohme LLC · 2 shared drug classes
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) · 1 shared drug class
Aronora, Inc. · 1 shared drug class
Aclaris Therapeutics, Inc. · 1 shared drug class
AmMax Bio, Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Astellas Pharma Global Development, Inc.:

Cite this brief

Drug Landscape (2026). Astellas Pharma Global Development, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/astellas-pharma-global-development-inc. Accessed 2026-06-10.